The previous studies have also identified additional miR-185 target genes, such as RhoA, Cdc42, and Stim1 [65–69], that are pro-hypertrophic in the heart, suggesting further that miR-185 is a strong anti-hypertrophic miRNA in vivo and a potent therapeutic target for cardiac diseases. Here, CDC42 is linked to heart disorder.